Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News ArQule Inc. ARQL

Healthcare Biotechnology

Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ARQL)

FDA Grants Rare Pediatric Disease Designation to ArQule’s Miransertib (ARQ 092) for the Treatment of Proteus Syndrome

Business Wire November 1, 2017

ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017

Business Wire October 26, 2017

ArQule Announces $15.7 Million Private Placement of Common Stock

Business Wire October 16, 2017

ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017

Business Wire September 19, 2017

ArQule Reports Second Quarter 2017 Financial Results

Business Wire August 4, 2017

Investor Network: ArQule, Inc. to Host Earnings Call

Accesswire August 4, 2017

ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017

Business Wire July 21, 2017

ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies

Business Wire July 11, 2017

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

PR Newswire June 26, 2017

ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)

Business Wire June 23, 2017

ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases

Business Wire June 7, 2017

ArQule Presents Phase 1/2 Clinical Data with ARQ 087 in Intrahepatic Cholangiocarcinoma at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire June 3, 2017

ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)

Business Wire May 18, 2017

ArQule to Present Clinical Data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

Business Wire May 17, 2017

Investor Network: ArQule, Inc. to Host Earnings Call

Accesswire May 3, 2017

Arqule Reports First Quarter 2017 Financial Results

Business Wire May 3, 2017

ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531

Business Wire April 26, 2017

ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531

Business Wire April 11, 2017

ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017

Business Wire March 28, 2017

ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan

Business Wire March 27, 2017